Table 2 Comparison of the baseline parameters in the subgroups of ACR30 responders and non-responders after 12 weeks of treatment
|  | ETA + MTX, week 12 ACR30 responders (n = 33) | Placebo + MTX, week 12 ACR30 responders (n = 20) | Placebo + MTX, week 12 ACR30 non-responders (n = 12) | p |
|---|---|---|---|---|
Number of joints with LOM | 8 (5–17) | 6 (4–7.5) | 5 (3.5–10.5) | 0.030 |
Tender joint count | 10 (5–19) | 6 (4–8) | 6 (3.5–10.5) | 0.023 |
VAS disease Activity (physician’s) | 8 (6–9) | 6 (6–7) | 6.5 (4.5–8) | 0.036 |
JADAS-71 | 24 (19–34) | 19.3 (19–23.8) | 17 (14–27) | 0.020 |
CRP level | 3.6 (1–26) | 1.6 (0.7–9.4) | 1.1 (0.1–2.9) | 0.031 |